MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2026 International Congress

    Cross-Cultural Validation of the Hebrew version of The International Parkinson and Movement Disorder Society Non-Motor Rating Scale

    VL. Livneh, A. Ezra, H. Lentschitzky, A. Socher, A. Thaler, A. Hilel, H. Shabtai, J. Zitser, G. Eshed, T. Shainer, P. Ponger, R. Alcalay, Y. Manor, V. Rozani, S. Luo, C. Goetz, G. Stebbins, P. Martin, T. Mestre, A. Ferro (Tel Aviv, Israel)

    Objective: This study aims to validate the Hebrew version of the MDS-NMS and make it suitable for use in Hebrew speaking population Background: Parkinson's disease is a complex neurodegenerative disease with…
  • 2026 International Congress

    A 6-month Pilot Study of Disease-Modifying Potential of Long-term Transcutaneous Auricular Vagus Nerve Stimulation in Parkinson’s Disease

    JX. Shi, KZ. Zhang (Nanjing, China)

    Objective: To investigate the efficacy and potential disease-modifying effects of of long-term transcutaneous auricular vagus nerve stimulation(taVNS) in patients with early-stage Parkinson's Disease(PD). Background: PD currently lacks established disease-modifying…
  • 2026 International Congress

    7 Tesla MRI with Quantitative Susceptibility Mapping: Quantitative focal measurements and qualitative grading of the substantia nigra as a biomarker for Parkinson’s Disease

    R. Unsgård, K. Stige, A. Kristoffersen, P. Goa, C. Tzoulis, E. Berntsen (Trondheim, Norway)

    Objective: To quantitatively and qualitatively evaluate susceptibility changes in the dorsal SN (dSN), using quantitative susceptibility mapping (QSM) and susceptibility-weighted imaging (SWI) at 7Tesla (7T)…
  • 2026 International Congress

    Escitalopram for Depression and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta‑analysis

    V. Byroju, J. Pitton Rissardo, J. Patino, A. Fornari Caprara, A. Mcgarry, I. Walker (Camden, USA)

    Objective: To evaluate the efficacy of escitalopram versus placebo for depressive symptoms, motor severity, and quality of life (QoL) in Parkinson’s disease (PD). Background: Depression…
  • 2026 International Congress

    Demystifying the Delivery of Multi-arm Multi-stage Platform Trials for Parkinson’s Disease –Framework and Recommendations from EJS ACT-PD

    C. Girges, J. Inches, L. Brennan, G. Mills, M. Zeissler, E. de Pablo-Fernandez, C. Pugh, C. Gonzalez-Robles, R. Gurney, S. Collins, C. Murphy, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To develop a framework of protocol-aligned rater training, educational resources, and inter-site engagement (Stage 1). The secondary aim was to assess the perceived usefulness…
  • 2026 International Congress

    Real-World Clinical Outcomes and Patient Experience Following Hybrid DBS Conversion to a Neurostimulator with Advanced Current Steering

    J. Vesper, A. Dreyer, R. Shivacharan, E. Goldberg (Düsseldorf, Germany)

    Objective: In this report, we describe preliminary real-world clinical outcomes and patient experience following hybrid DBS conversion procedures at our center. Background: Hybrid replacement procedures…
  • 2026 International Congress

    Biochemical and Nutritional Changes During Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: Findings from an Observational Cohort

    O. Phokaewvarangkul, N. Rattanapitak, P. Kuwattanasuchati, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate the clinical effectiveness of CSAI and associated changes in vitamin B status, homocysteine (Hcy) levels, and nutritional outcomes in patients with advanced…
  • 2026 International Congress

    Speech and Voice Changes after Intensive Therapy in Parkinson’s Disease

    L. Tadmor, O. Sella Weiss, Y. Ashkenazi, L. Yaakov, N. Stainer, T. Thies (Cologne, Germany)

    Objective: To examine the effects of a modified intensive speech therapy program on perceptual and objective acoustic measures in Hebrew-speaking individuals with Parkinson’s disease (PD).…
  • 2026 International Congress

    Comorbid Diabetes Exacerbates Motor and Nonmotor Dysfunction in Parkinson’s disease- a Cross-sectional Study

    S. Krishnan, S. Veena, A. Vijayaraghavan, S. Sachithanandan, D. Puthenveedu (Thiruvananthapuram, India)

    Objective: To compare the severity of motor and nonmotor manifestations of Parkinson’s disease (PD) in Indian patients with and without comorbid Type 2 Diabetes Mellitus…
  • 2026 International Congress

    Dropped Head Syndrome From Combined MT‑TE and MT‑ND1 Mitochondrial Variants

    J. Chen, W. Tse (New York, USA)

    Objective: To report a case of dropped head syndrome (DHS) associated with both Parkinson's Disease (PD) and biopsy-proven mitochondrial myopathy in a patient carrying coexisting…
  • « Previous Page
  • 1
  • …
  • 60
  • 61
  • 62
  • 63
  • 64
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley